In-licensing asset scouting for biotech & pharma BD
Seeing the same assets as every other buyer?
Three unpartnered assets matched to your focus. If this isn't a fit for your mandate, I'll tell you.
Owners are contacted without your name until you approve. We agree a seen list up front, so there's never a question of who found what. Your team does the science and the negotiation.
Licensing opportunities posted at BIO-Europe 2025: the same pool every buyer at the event sees.
Informa / EBD GroupOne-to-one partnering meetings at the same event. Plenty of volume, mostly with owners already pitching everyone.
Informa / EBD GroupOf US in-licensing transactions in 2025 were sourced from Chinese partners, a channel now facing new US policy scrutiny.
GlobalData via ReutersThe real bottleneck
The decks keep coming and the partnering calendar is full. But the owners pitching at BIO and JPM are pitching every buyer in the room, and the assets that fit your criteria often sit with people who never send a deck: an academic lab with a fresh grant on your target, a small biotech that stopped marketing, a company in Korea, Japan or Latin America that doesn't use Western partnering systems. Reaching them takes proactive outbound, and proactive outbound takes senior hours your team doesn't have.
In-Licensing Asset Scouting
Asset owners who don't pitch at partnering events, mapped against your written criteria, contacted without your name until you approve, and qualified on a call before they ever reach your inbox. Your team does the science and the negotiation. I do the finding.
That's the whole offer, in a sentence. Every part of it is built to remove the reason BD teams hesitate: not the price, but the risk to your company's name, your pipeline priorities, and the credit for the find.
Why us
If an outside scout didn't work for you before, it usually failed for the same three reasons: names you already knew, a representative you couldn't control, and a fee dispute waiting to happen. This is built to answer each one directly.
Academic labs and tech transfer offices, small biotechs, and Asian and Latin American companies that rarely show up in partnering systems. The point is reach, not volume.
I work for one company per area, cut by indication, modality, stage and territory if needed. Your search is never run for a competitor at the same time.
You don't get a 1,500-row spreadsheet. Every owner I introduce has been spoken to, asked about rights and availability, and written up in a brief you can review.
How it works
We write down what fits: therapeutic area, modality, stage, territory and rights. If this isn't a fit for your mandate, you'll hear that.
From public sources: trial registries, university tech transfer listings, and company pipelines in Asia, Latin America and the West. Each asset is scored against your criteria.
Owners hear a description you approved, not your name. I qualify each one on a call: interest, rights, availability, and what they can share now.
A written brief per qualified asset. You decide pursue or pass, and I introduce only the owners you approve. Your team takes it from there.
What you get
A long list sells volume. This is a short list you can stand behind, because every owner on it has been spoken to and every introduction happens on your terms.
The asset, the owner, stage, rights position, what's shareable now, and what the owner said on the call, so you're making a reviewable decision, not reading a cold deck.
Before outreach starts, we list what you already know. Anything on it is never mine to claim, so there's never a question of who found what.
You approve exactly how your company is described to owners before anyone is contacted. Nobody speaks for you in words you didn't sign off on.
Owners don't learn your name until you approve it, asset by asset. Your pipeline priorities stay yours.
Exclusivity cut by indication, modality, stage and territory, so the assets I find for you aren't offered to a competitor through me.
You mark each brief pursue or pass, and a monthly status report shows owners contacted, qualified and introduced. Results are counted in qualified conversations, not rows.
The pilot
If it isn't working, you stop. No drama.
We start with a 60–90 day pilot on a monthly retainer. Results are measured in qualified owner conversations, the thing I actually control, not in list length. The success fee applies only to a signed license or option. If the pilot isn't producing owners worth your time, you stop at the end of it.
One honest note: this only works for teams with a live in-licensing mandate and criteria we can write down. On the call I'll tell you plainly if it isn't a fit.
Request a free sample briefYour name, your priorities
Most outside scouting skips this question entirely, which is exactly why BD leaders don't bite. I raise it before you have to. My role is deliberately kept to finding, qualifying and introducing. Everything that represents your company or commits it stays with you.
I work only for operating pharma and biotech companies. I don't represent asset owners or investors, so there's no other side of the table I'm working for.
Straight talk
I'm building this the honest way, so I'm not going to fabricate client logos or testimonials. Here's why it works anyway: I've removed the reasons outside scouting normally goes wrong. You approve how you're described, so nobody misrepresents you. The seen list is agreed up front, so a fee dispute can't start. Exclusivity means your search isn't run for anyone else in your area. And because results are counted in qualified conversations, you're never paying for a spreadsheet of names you already knew.
I'm also the person doing the outreach. You're not buying access to a platform or a database. You're getting one operator whose whole job is reaching the owners your usual channels miss and bringing you only the ones worth your time.
Fit
Why now
Partnering season shows every buyer the same assets. The owners who skip it are the ones worth reaching first.
There's no manufactured countdown here. It's just the calendar: BIO-Europe in November and JPM in January put the same assets in front of everyone, and next year's BD budgets get set this quarter. I take one client per therapeutic area, so once an area is taken, it's taken.
Questions
In words you approve before any outreach starts. By default, owners hear a neutral description of what you're looking for, not your name. Your name is shared only when you approve it, owner by owner.
Then it isn't mine to claim. Before outreach starts, we agree a seen list of the assets and owners you already know. Anything on it is excluded from the success fee, so there's never a question of who found what.
Your team does. I find, qualify and introduce; I don't judge the science or claim to know your therapeutic area better than you do. The brief gives you what you need to decide quickly whether a scientific look is worth your time.
No. I work only for operating pharma and biotech companies looking to in-license. I don't take fees from asset owners and I don't work for investors, so my incentive is only ever on your side.
Directly. I work through public sources most buyers don't cover systematically (trial registries, university tech transfer listings, grant records, and company pipelines in Korea, Japan, Latin America and elsewhere), then reach each owner personally and qualify them on a call. Sourcing isn't limited to China, so you're not dependent on one channel.
A 60–90 day pilot on a monthly retainer, plus a success fee only on a signed license or option. Exact numbers are quoted on the call once we've agreed your criteria. The sample brief is free.
Yes. The pilot exists so you can judge results in qualified owner conversations before committing to anything longer. If it isn't working, you stop.
Get a sample brief
Book a short call. We agree what fits your mandate, and I come back with a free sample brief: three unpartnered assets matched to your criteria. If this isn't a fit for your team, you'll know that too, and you'll have lost nothing but a few minutes.
No charge, no obligation. Your name is never used in outreach without your approval.